Key result
Factor XI/XIa inhibitors offer potential advantages over DOACs in stroke prevention, such as reduced bleeding and fewer drug interactions, though clinical trials must still demonstrate non-inferiority.
Why the study?
Standard of care antithrombotic therapies are underutilized and limited by bleeding rates, drug interactions, and renal elimination, creating interest in FXI/XIa inhibitors that may reduce bleeding while maintaining efficacy.
Do Factor XI/XIa inhibitors provide effective stroke prevention with improved safety compared to DOACs?
Do Factor XI/XIa inhibitors provide effective stroke prevention with improved safety compared to DOACs?
Answers are grounded in this paper and cite their sources.
Factor XI/XIa inhibitors are a promising novel class of anticoagulants that may reduce bleeding risks compared to current standard-of-care DOACs.
INTRODUCTION: Antithrombotic therapy is the cornerstone of stroke prevention, but standard of care therapies are underutilized and use is limited by bleeding rates, drug interactions, and renal elimination. Factor XI/XIa (FXI/XIa) inhibitors are a novel anticoagulation class that purportedly target thrombosis more than hemostasis, thereby raising the hope of reducing bleeding consequences while maintaining efficacy. AREAS COVERED: This review covers the mechanistic rationale for FXI/XIa inhibitors, describes the various molecule sub-classes, addresses barriers to current anticoagulation use, and reviews clinical trial data to date for this novel class of anticoagulants. EXPERT OPINION: FXI/XIa inhibitors offer several advantages over DOACs in stroke prevention such as reduced bleeding, fewer drug interactions, and less renal elimination. However, clinical trials must demonstrate non-inferior efficacy and improved safety compared to DOACs. Additional barriers to use will include cost, inadequacy of antidotes, and overall anticoagulant underutilization. The potential for a small molecule or monoclonal antibody to reach the clinic is very high.
No takes yet. Share an insight, caveat, or question.
Gibson et al. (2025) conducted a review in Stroke prevention. Factor XI/XIa inhibitors vs. DOACs was evaluated. Factor XI/XIa inhibitors offer potential advantages over DOACs in stroke prevention, such as reduced bleeding and fewer drug interactions, though clinical trials must still demonstrate non-inferiority.
Synapse has enriched 10 related papers. Consider them for comparative context: